Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Non-Current Deffered Revenue (2016 - 2026)

Gyre Therapeutics has reported Non-Current Deffered Revenue over the past 11 years, most recently at $852000.0 for Q4 2025.

  • Quarterly Non-Current Deffered Revenue fell 8.19% to $852000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $852000.0 through Dec 2025, down 8.19% year-over-year, with the annual reading at $852000.0 for FY2025, 8.19% down from the prior year.
  • Non-Current Deffered Revenue was $852000.0 for Q4 2025 at Gyre Therapeutics, down from $866000.0 in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $928000.0 in Q4 2024 and troughed at $118000.0 in Q4 2022.
  • The 4-year median for Non-Current Deffered Revenue is $532500.0 (2023), against an average of $534600.0.
  • The largest YoY upside for Non-Current Deffered Revenue was 368.11% in 2025 against a maximum downside of 8.19% in 2025.
  • A 4-year view of Non-Current Deffered Revenue shows it stood at $118000.0 in 2022, then surged by 80.51% to $213000.0 in 2023, then surged by 335.68% to $928000.0 in 2024, then dropped by 8.19% to $852000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Non-Current Deffered Revenue are $852000.0 (Q4 2025), $866000.0 (Q3 2025), and $884000.0 (Q2 2025).